Rarecells, Inc. Makes a Significant Breakthrough: Identification of Circulating Giant Cancer Cells Found in Patients with MDS
Friday, July 21, 2023
Rarecells, Inc. is excited to share a groundbreaking discovery made in collaboration with Dr. Azra Raza's team from Columbia University Irving Medical Center. Their joint research has unveiled, for the first time, the presence of circulating giant cancer cells (CGCCs) in patients with Myelodysplastic Syndrome (MDS) who are at risk of developing acute myeloid leukemia (AML). The research article, titled "Circulating cancer giant cells with unique characteristics frequently found in patients with myelodysplastic syndromes (MDS)", has been published in the Medical Oncology journal.
The study utilized Rarecells' highly sensitive proprietary ISET® technology to successfully isolate circulating Giant Cells. MDS, a group of blood diseases that are currently incurable and can progress to AML, was the main focus of this collaborative investigation. The study effectively identified tumor markers on circulating Giant Cells in MDS patients, thus establishing their cancerous nature. Notably, these particular tumor markers were not detected in the circulating Giant Cells of healthy individuals.
This publication marks the culmination of several years of collaborative research and stands as a significant contribution to the understanding of Giant Cells and liquid cancers. The findings hold immense potential for advancing early detection methods and the development of more targeted and precise treatments, ultimately improving patient outcomes and potentially saving lives.